Accelerator physics

Best Cyclotron Systems Announces Successful Completion of Initial Factory Acceptance Test for B6–15 MeV Proton Cyclotron

Retrieved on: 
Wednesday, July 7, 2021
Research, Medical devices, Hospitals, Other Health, Biotechnology, General Health, Health, Science, Oncology, Other Science, Particle accelerators, Accelerator physics, Physics, Physical sciences, Cyclotron, Nuclear medicine, Academic disciplines

On June 30, 2021, teams from Best Cyclotrons Systems (BCS in Vancouver, Canada) and sister-company Best Theratronics Ltd. (BTL in Ottawa, Canada) of TeamBest Global Companies (TBG), successfully completed the initial Factory Acceptance Test (FAT) for their novel Best 615 MeV Proton Cyclotron for a National Lab.

Key Points: 
  • On June 30, 2021, teams from Best Cyclotrons Systems (BCS in Vancouver, Canada) and sister-company Best Theratronics Ltd. (BTL in Ottawa, Canada) of TeamBest Global Companies (TBG), successfully completed the initial Factory Acceptance Test (FAT) for their novel Best 615 MeV Proton Cyclotron for a National Lab.
  • Krishnan Suthanthiran, President & Founder of TBG Companies said, "Today is a fantastic day, as the BCS-Vancouver and BTL-Ottawa teams worked flawlessly together in accomplishing the successful Factory Acceptance Test for the newest B6-15p Cyclotron, a very high current, variable energy system.
  • The New Best 615 MeV Variable Energy Cyclotron is a Shielded, Compact, High Current, Multi-Use Proton Cyclotron System, capable of producing a variety of medical isotopes for diagnosis and therapy, as well as generating neutron beams.
  • For more information about TeamBest Global Companies, Best Cyclotron Systems and Best Theratronics Ltd., please visit:

Helion Energy Achieves 100 Million Degrees Celsius Fusion Fuel Temperature and Confirms 16-Month Continuous Operation of Its Fusion Generator Prototype

Retrieved on: 
Tuesday, June 22, 2021
Other Energy, Utilities, Environment, Alternative energy, Energy, Engineering, Nuclear, Manufacturing, Fusion power, Physical sciences, Physics, Natural sciences, Plasma physics, Divertor, Accelerator physics, Nuclear fusion, Nuclear physics, Helion

Helion Energy (Helion), a clean electricity company committed to creating a new era of clean energy through fusion, today became the first private company to announce exceeding 100 million degrees Celsius in their 6th fusion generator prototype, Trenta.

Key Points: 
  • Helion Energy (Helion), a clean electricity company committed to creating a new era of clean energy through fusion, today became the first private company to announce exceeding 100 million degrees Celsius in their 6th fusion generator prototype, Trenta.
  • Reaching this temperature is a critical engineering milestone as it is considered the ideal fuel temperature at which a commercial power plant would need to operate.
  • View the full release here: https://www.businesswire.com/news/home/20210622005366/en/
    The Divertor of Trenta, Helion's 6th fusion generator prototype.
  • Lastly, this presentation will phenomenologically discuss the operational results of the Mark-I scientific divertor with a focus on long-term operation.

An Open Letter to Users of Cyclotrons (up to 20 MeV), PETNET, Nuclear Pharmacy & PET/CT for Their Radioisotope Needs

Retrieved on: 
Tuesday, April 27, 2021
Medical devices, Hospitals, Health, Radiology, Oncology, Nuclear medicine, Medicine, Physical sciences, Medicinal radiochemistry, Medical physics, Neuroimaging, Accelerator physics, Particle accelerators, Cyclotron, Positron emission tomography, Radioactive tracer, PET-CT

b"Best ABT, a company of TeamBest Global (TBG) Group, is planning to introduce a new cyclotron \xe2\x80\x94 the Best Sub-Compact Model 200 \xe2\x80\x94 which can fulfill a hospital\xe2\x80\x99s needs for PET imaging and other similar small cyclotrons.

Key Points: 
  • b"Best ABT, a company of TeamBest Global (TBG) Group, is planning to introduce a new cyclotron \xe2\x80\x94 the Best Sub-Compact Model 200 \xe2\x80\x94 which can fulfill a hospital\xe2\x80\x99s needs for PET imaging and other similar small cyclotrons.
  • The new cyclotron will have a push-button control and one or more chemistry boxes that can be placed near the PET/CT, eliminating the need to transport radioisotopes from the cyclotron operation to PET/CT locations.
  • The Best Model 200 is self-shielded, with an internal ion source.
  • This is the only such cyclotron in the world.

JEOL: Release of Electron Beam Metal AM Machine “JAM-5200EBM”

Retrieved on: 
Friday, March 26, 2021
Semiconductor, Engineering, Technology, Manufacturing, Other Manufacturing, Hardware, Electron, Electron beam, Physical sciences, Science, Microscopes, Accelerator physics, Anatomical pathology, Electron microscope, Pathology, JEOL, Electron-beam lithography, Cathode ray

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of Electron Beam Metal AM Machine JAM-5200EBM from March 26, 2021.

Key Points: 
  • JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of Electron Beam Metal AM Machine JAM-5200EBM from March 26, 2021.
  • Using technology of the world's highest level performance electron microscope and electron beam lithography system for semiconductor manufacturing, JEOL has developed an "Electron Beam Metal AM Machine" with higher power, higher density and higher speed.
  • Moreover, thanks to the long life cathode*1 and helium-free, cost reduction and mass production of parts of high quality and reproducibility are achieved.
  • The technology developed in our electron microscope and electron beam lithography system for semiconductor manufacturing has enabled us to automatically adjust the focus and the distortion of the electron beam.

Asia Pacific Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 24, 2021
Health, General Health, Particle accelerators, Accelerator physics, Cyclotron, Nuclear medicine, Trend

The "Asia Pacific Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type; Capacity; End User, and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type; Capacity; End User, and Country" report has been added to ResearchAndMarkets.com's offering.
  • The report highlights trends prevailing in the Asia Pacific medical cyclotron market and the factors driving market along with those that act as hindrances.
  • Determine prospective investment areas based on a detailed trend analysis of the Asia Pacific medical cyclotron market over the next years.
  • Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Asia Pacific medical cyclotron market.

IONETIX Announces Targeted Alpha Therapy Manufacturing Center

Retrieved on: 
Tuesday, March 16, 2021
Physical sciences, Natural sciences, Physics, Nuclear medicine, Accelerator physics, Medical physics, Particle accelerators, Nuclear technology, Targeted alpha-particle therapy, Cyclotron, Lansing, Michigan, Radionuclide

ft. facility in Lansing, MI for its new Targeted Alpha Radionuclide Manufacturing Center.

Key Points: 
  • ft. facility in Lansing, MI for its new Targeted Alpha Radionuclide Manufacturing Center.
  • IONETIX is currently developing a 30MeV cyclotron utilizing the same proprietary cyclotron technology platform employed in their ION 12SC cyclotron.
  • Targeted Alpha Therapy has the potential to be a life-changing and life-saving cancer treatment option to which IONETIX can make great contributions.
  • The new Targeted Alpha Radionuclide Manufacturing Center is slated to open in early 2022 and will create over 30 new skilled jobs in the Lansing area once fully operational.

Worldwide Medical Cyclotron Industry to 2027 - Availability of Technologically Advanced Diagnostic Devices Presents Opportunities

Retrieved on: 
Tuesday, March 16, 2021
Particle accelerators, Companies, Accelerator physics, Industry economics), Advanced Cyclotron Systems, Manufacturing, Cyclotron, Varian Medical Systems, Siemens

According to this report the global medical cyclotron market is expected to reach US$ 238.21 million by 2027 from US$ 180.00 million in 2019.

Key Points: 
  • According to this report the global medical cyclotron market is expected to reach US$ 238.21 million by 2027 from US$ 180.00 million in 2019.
  • Based on capacity, the medical cyclotron market is segmented into 10-12 MeV, 16-18 MeV, 19-24 MeV, and 24 MeV and above.
  • The demand for medical cyclotron with 16-18 MeV capacity is increasing as it offers maximum capacity and consistent yields.
  • General Electric Company; Varian Medical Systems, Inc; IBA; Sumitomo Heavy Industries, Ltd; Siemens AG; Advanced Cyclotron Systems; isoSolution Inc; ALCEN; Ionetix Corporation, and Best Cyclotron Systems, Inc. are among the leading companies operating in the medical cyclotron market.

Global Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, March 12, 2021
Medical devices, Health, Particle accelerators, Accelerator physics, Cyclotron, Nuclear medicine, MEV, Physics, Physical sciences, Academic disciplines

The "Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, Capacity, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Cyclotron Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, Capacity, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • According to this report the global medical cyclotron market is expected to reach US$ 238.21 million by 2027 from US$ 180.00 million in 2019.
  • Based on capacity, the medical cyclotron market is segmented into 10-12 MeV, 16-18 MeV, 19-24 MeV, and 24 MeV and above.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Cyclotron launches unified security administration and governance - TeamsHub by Cyclotron Secure

Retrieved on: 
Thursday, February 18, 2021
Computing, Technology, Computer companies, Accelerator physics, Particle accelerators, Cyclotron, Nuclear medicine, Cloud computing, Microsoft, Computer security

Due to the changing work patterns with more remote or flex workers, online security has become even more important.

Key Points: 
  • Due to the changing work patterns with more remote or flex workers, online security has become even more important.
  • It has been the DNA of our product with each and every release of TeamsHub by Cyclotron," added Logu Krishnan, Director of Technology.
  • "TeamsHub by Cyclotron Secure is the ultimate security experience for the entire organization.
  • TeamsHub by Cyclotron is a unified platform that caters to automated governance, administration and security of Microsoft Cloud.

Varian Installs World's First ProBeam® 360° Proton Therapy System at Penn Medicine Lancaster General Health

Retrieved on: 
Thursday, February 4, 2021
Medicine, Medical physics, Proton, Proton therapy, Accelerator physics, Physics, Cyclotron, Gantry

PALO ALTO, Calif., Feb. 4, 2021 /PRNewswire/ --Varian (NYSE: VAR) has started the installation of the cyclotron and gantry for its ProBeam 360 single-room proton therapy systemat Penn Medicine Lancaster General Health's Ann B. Barshinger Cancer Institute.

Key Points: 
  • PALO ALTO, Calif., Feb. 4, 2021 /PRNewswire/ --Varian (NYSE: VAR) has started the installation of the cyclotron and gantry for its ProBeam 360 single-room proton therapy systemat Penn Medicine Lancaster General Health's Ann B. Barshinger Cancer Institute.
  • The cyclotron and gantry are core pieces of equipment of the ProBeam 360 system.
  • The Ann B. Barshinger Cancer Institute, which is part of Penn MedicineLancasterGeneral Health,has become the first treatment center in the world to have a ProBeam 360 system from Varian.
  • "Varian is proud of our longstanding collaboration with Penn Medicine, which goes back decades and encompasses joint innovation, clinical research, training and education, and bringing new technologies to cancer patients," said Kolleen Kennedy, Chief Growth Officer and President of Proton Therapy Solutions at Varian.